Does Medicaid cover Mounjaro in New York?

If you’re considering GLP-1 medications like Wegovy, Ozempic, or Mounjaro for weight loss or diabetes management, you’re probably wondering: Will my insurance actually cover this? With monthly costs exceeding $1,000 without coverage, understanding your insurance benefits isn’t just helpful—it’s essential.

The short answer: It depends on your medication, diagnosis, insurance type, and state. Let’s break down exactly what you need to know about GLP-1 coverage in 2025.

Understanding GLP-1 Medications: Same Drug, Different Uses

Before diving into insurance coverage, it’s important to understand that these medications fall into two categories based on FDA approval:

For Type 2 Diabetes:

• Ozempic (semaglutide)
• Mounjaro (tirzepatide)

For Weight Loss:

• Wegovy (semaglutide—same as Ozempic, different dose)
• Zepbound (tirzepatide—same as Mounjaro, different dose)

This distinction matters tremendously for insurance coverage. Insurers generally cover diabetes medications as essential treatments, but weight-loss medications face significant restrictions or outright exclusions.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Commercial Insurance Coverage: What to Expect

Wegovy (For Weight Loss)

Coverage Status: Limited and Heavily Restricted

Most commercial health plans treat Wegovy as an optional benefit, not a requirement. According to recent data, many employer-sponsored plans either exclude obesity medications entirely or implement strict coverage criteria to manage costs.

When Wegovy IS covered, you’ll typically need:

• BMI of 30 or higher (or 27+ with at least one weight-related condition like hypertension, type 2 diabetes, or high cholesterol)
• Documented 6-month supervised diet and exercise program with insufficient weight loss
• Prior authorization from your insurance company
• Step therapy requirements (trying older, cheaper weight-loss medications first in many cases)
• Regular follow-ups proving 5% or greater weight loss to maintain coverage

Typical tier placement: Tier 3-4 (non-preferred brand or specialty), meaning higher copays—often $100-$500 per month even with insurance.

Ozempic (For Type 2 Diabetes)

Coverage Status: Widely Covered for Approved Use

Since Ozempic is FDA-approved for type 2 diabetes, most commercial plans cover it as part of their pharmacy benefits. However, insurers have implemented safeguards to prevent off-label use for weight loss.

Coverage requirements typically include:

• Confirmed type 2 diabetes diagnosis
• Prior authorization to verify the diagnosis and rule out weight-loss-only use
• Evidence of inadequate control on first-line diabetes medications (like metformin)
• Step therapy in some plans—trying other diabetes medications before GLP-1s

What won’t be covered: Using Ozempic solely for weight loss. If you don’t have diabetes, your claim will be denied. Insurers have become increasingly vigilant about denying off-label weight-loss requests for Ozempic.

Typical tier placement: Tier 3 (preferred or non-preferred brand), with copays ranging from $50-$200 per month.

Mounjaro (For Type 2 Diabetes)

Coverage Status: Covered with Restrictions

Like Ozempic, Mounjaro is covered for type 2 diabetes but not for weight loss (insurers direct weight-loss patients to Zepbound, if covered at all).

Coverage criteria mirror Ozempic:

• Type 2 diabetes diagnosis required
• Prior authorization is almost universal given the high cost
• Step therapy—many plans require trying Ozempic or other GLP-1s first, as Mounjaro is newer and more expensive
• Regular monitoring of A1c levels and treatment response

Typical tier placement: Tier 3-4 (specialty tier on many plans), with monthly copays potentially reaching $200-$500.

Medicare Coverage: The Obesity Drug Exclusion

Medicare Part D does NOT cover medications prescribed solely for weight loss. This is a legal restriction under the Social Security Act, which excludes ‘drugs used for weight loss’ from Part D coverage.

The exception: Medicare will cover Wegovy (and potentially Zepbound) when prescribed for FDA-approved uses beyond weight loss. As of March 2024, Wegovy gained approval for reducing cardiovascular risk in obese patients with established heart disease. Medicare Part D covers Wegovy for this specific indication—not for general weight management.

For diabetes medications:

• Ozempic and Mounjaro ARE covered under Part D for type 2 diabetes treatment
• Typical tier placement: Tier 3 or specialty tier
• Prior authorization and step therapy requirements vary by Part D plan
• Monthly copays during the coverage gap can be substantial ($100-$400)

Medicare Advantage plans (Part C) have slightly more flexibility and some began offering limited obesity medication coverage in 2025, but this varies significantly by plan.

Medicaid Coverage: A State-by-State Patchwork

Medicaid coverage for GLP-1 weight-loss medications varies dramatically by state, and the landscape is shifting rapidly due to budget pressures.

States That Cover Wegovy (with Strict Prior Authorization)

New York

• ✅ Covers Wegovy with prior authorization
• Requirements: BMI ≥30 or ≥27 with comorbidity, documented lifestyle modification
• Quantity limits: 4 pens per 28 days
• Status: Ongoing coverage as of 2025

Pennsylvania

• ⚠️ Covered through December 2025 ONLY
• Currently requires BMI ≥30 (or ≥27 + comorbidity), weight-related conditions, and documented diet/exercise attempts
• Coverage ENDS January 1, 2026 due to state budget cuts
• If you have diabetes, must try diabetes-indicated GLP-1s first

States That Recently Eliminated Coverage

California

• 🔒 Coverage ENDS January 1, 2026
• Previously covered with BMI ≥30 (or ≥27 + comorbidity) and 6-month supervised program
• Adult coverage being eliminated; pediatric patients may still access via EPSDT exception
• Decision made to reduce Medicaid spending

States That Do Not Cover Weight-Loss Medications

Texas

• ❌ Excludes all obesity medications for adults (age 21+)
• Policy in effect since March 2023
• Pediatric exceptions possible via EPSDT (Early and Periodic Screening, Diagnostic, and Treatment)

Florida

• ❌ Does not cover any anti-obesity medications
• Uses federal exclusion option under Social Security Act
• Only diabetes-indicated GLP-1s (Ozempic, Mounjaro) covered, and only for type 2 diabetes

Illinois

• ❌ No Medicaid coverage for weight-loss drugs
• 2023 legislation expanded coverage for state employees only, not Medicaid enrollees

According to recent analyses, only about 13 states cover GLP-1 medications for obesity in their Medicaid programs, and several are actively scaling back or eliminating this coverage due to costs that can exceed tens of millions of dollars annually.

The Most Common Reasons Insurance Denies GLP-1 Claims

Understanding why claims get denied helps you avoid these pitfalls and build a stronger case if you need to appeal.

1. Not Meeting BMI Requirements

Most plans require documented BMI of 30+ (or 27+ with specific comorbidities). A single doctor’s note isn’t always sufficient—insurers may require:

• BMI calculations from multiple visits
• Height and weight measurements taken in the provider’s office (not self-reported)
• Documentation that comorbidities are current and clinically significant

2. Insufficient Documentation of Prior Weight-Loss Attempts

Nearly all plans covering Wegovy require proof of at least 6 months of supervised diet and exercise programs with insufficient weight loss. Insurers want to see:

• Regular visits with a provider or registered dietitian
• Documentation of specific diet plans and caloric intake
• Exercise logs or fitness assessments
• Proof that these interventions didn’t result in significant weight loss

Simply stating ‘patient tried diet and exercise’ won’t suffice. Detailed medical records are essential.

3. Missing Step Therapy Requirements

Many insurers require trying cheaper alternatives first:

• For weight loss: older medications like phentermine, orlistat, or liraglutide (Saxenda)
• For diabetes: metformin, sulfonylureas, or SGLT2 inhibitors before GLP-1s
• For Mounjaro specifically: some plans require trying Ozempic first

If your medical record doesn’t show these prior medication trials, the claim may be denied.

4. Off-Label Use Without Proper Diagnosis

Using Ozempic or Mounjaro for weight loss when you don’t have type 2 diabetes will almost certainly result in denial. Insurers cross-reference diagnosis codes with medication indications and reject claims that don’t align.

5. Plan Exclusions

Some employer plans explicitly exclude ‘drugs for weight management’ or ‘anti-obesity agents’ from their formularies. In these cases:

• No amount of medical necessity can override the exclusion
• Your only option is paying out-of-pocket or seeking alternative medications
• Employers would need to add coverage during open enrollment

How to Appeal a Denial Successfully

If your claim is denied, don’t give up. Appeal success rates can be significant when you truly meet the criteria.

Step 1: Request a Detailed Explanation

Contact your insurance company and ask for:

• The specific reason for denial (diagnosis code mismatch, missing documentation, etc.)
• The policy language or medical necessity criteria used
• Instructions for filing an appeal

Step 2: Gather Comprehensive Documentation

Work with your healthcare provider to compile:

• Complete medical history documenting weight struggles and related health conditions
• BMI calculations from multiple visits over time
• Detailed records of supervised diet and exercise programs (dates, providers, interventions, outcomes)
• Evidence of previous medication trials (if required by step therapy)
• Laboratory results showing related conditions (A1c for diabetes, lipid panels, blood pressure readings)
• Letter of medical necessity from your prescribing physician explaining why this medication is essential for your health

Step 3: Submit a Formal Appeal

Most insurers have two appeal levels:

• First-level (internal) appeal: Reviewed by a different person or department within the insurance company
• Second-level appeal: May involve an independent medical review

Submit your appeal in writing, include all supporting documentation, and keep copies of everything. Most insurers must respond within 30 days for standard appeals or 72 hours for expedited appeals (when delay would seriously jeopardize your health).

Step 4: Consider External Review

If internal appeals fail and you believe the denial is improper, you can:

• Request external review through your state insurance department (available in all states for ACA-compliant plans)
• File a complaint with your state insurance commissioner
• Seek assistance from patient advocacy organizations

Success factors: Appeals are most successful when:

• You genuinely meet all clinical criteria
• Documentation was initially incomplete but can be supplemented
• The denial was based on a technicality or error rather than a legitimate coverage exclusion

What About Telehealth? Will Insurance Cover Virtual Visits?

Good news: Most insurance plans now cover telehealth visits for weight management and chronic disease care.

Since the COVID-19 pandemic, telehealth coverage has expanded dramatically. Over 40 states have enacted telehealth parity laws requiring insurers to cover virtual visits the same as in-person care.

What this means for GLP-1 medications:

✅ Initial consultations with healthcare providers via video can typically be billed to insurance
✅ Follow-up appointments for medication management and weight monitoring are covered
✅ Nutritional counseling for obesity is an ACA-mandated preventive service, covered at no cost-sharing when provided by in-network providers (including via telehealth)
✅ Prescription writing during telehealth visits is accepted by insurers and pharmacies

Important considerations:

• Network status matters: Use in-network telehealth providers when possible to maximize coverage
• Visit type: Most plans require live video visits (not just phone calls or messaging) for full reimbursement
• State regulations: Some states have restrictions on prescribing controlled substances via telehealth, though GLP-1s are not controlled substances
• Platform variations: Some telehealth platforms (like Klarity Health) may operate on a cash-pay model for the visit itself, but the medication prescription can still be submitted to your insurance

At Klarity Health, we understand insurance navigation can be overwhelming. Our providers offer transparent pricing for telehealth visits and can prescribe GLP-1 medications when clinically appropriate, whether you’re using insurance or paying cash for your medication. We work with patients to understand their insurance benefits and explore all available cost-saving options.

Self-Pay Options: What If Insurance Won’t Cover It?

If insurance denies coverage or doesn’t include GLP-1s on your formulary, several programs can significantly reduce your out-of-pocket costs.

Manufacturer Savings Programs

Novo Nordisk (Wegovy & Ozempic):

• For insured patients: Savings card can reduce copays to as low as $0 per month (up to $225 monthly savings)
• For cash-pay patients: Through the NovoCare Wegovy Access Program, self-pay price is now $349 per month (reduced from the $1,350 list price)
• Patient assistance program: Free medication for uninsured patients meeting income criteria (typically <400% of federal poverty level)

Eli Lilly (Mounjaro & Zepbound):

• For insured patients with diabetes: Savings card can reduce Mounjaro copays to $25 per month
• For cash-pay patients: Single-dose Zepbound vials now available through LillyDirect for $299-$449 per month (depending on dose)
• Patient assistance program: Free medication for qualified low-income, uninsured patients

GoodRx Partnership Pricing

In November 2025, GoodRx launched an industry-changing program with Novo Nordisk:

• Introductory price: $199 per month for the first two months of Wegovy or Ozempic
• Ongoing price: $349 per month thereafter (60-70% discount from list price)
• Available at nearly all major pharmacies nationwide
• Combined telehealth option: GoodRx also offers a $39/month subscription that includes provider visits plus discounted medication prices

Other Cost-Saving Strategies

Pharmacy shopping: Prices can vary by hundreds of dollars between pharmacies. Use GoodRx, SingleCare, or other discount platforms to compare local prices.

Dose optimization: Some patients use lower maintenance doses once weight-loss goals are achieved (discuss with your provider—never adjust doses without medical guidance).

Alternative medications: Older weight-loss medications (phentermine, orlistat, naltrexone-bupropion) cost $30-$100 monthly and may be partially effective while you work on insurance approval for GLP-1s.

Caution on compounded medications: Some telehealth companies offer compounded semaglutide or tirzepatide at lower prices. These are NOT FDA-approved, may have quality and safety concerns, and insurance won’t cover them. The FDA has issued warnings about compounded GLP-1 medications.

Prior Authorization: What to Expect

If your insurance covers GLP-1 medications, prior authorization (PA) is almost universal. Here’s what the process typically looks like:

Timeline

• Initial review: 5-7 business days for most insurers
• Rush requests: 24-72 hours if medically urgent
• Appeals: 30 days for standard, 72 hours for expedited

Information Required

Your healthcare provider will need to submit:

✓ Diagnosis codes (E66.01 for obesity with BMI 30-34.9, E11.9 for type 2 diabetes, etc.)
✓ Current BMI calculation with date
✓ List of comorbid conditions
✓ Documentation of previous weight-loss attempts (dates, interventions, outcomes)
✓ Previous medication trials and reasons for discontinuation
✓ Rationale for why this specific medication is medically necessary
✓ Treatment plan including follow-up schedule

Common PA Outcomes

Approved: Typically for 3-6 months initially, requiring re-authorization with documented weight loss (usually 5% or greater) to continue

Partially approved: May approve a lower dose or shorter duration than requested

Denied: Most often due to missing documentation, not meeting BMI criteria, or insufficient prior treatment attempts

Peer-to-Peer Reviews

If initially denied, your doctor can request a peer-to-peer review—a conversation with the insurance company’s medical director to explain why the medication is necessary. These reviews have higher approval rates when clinical justification is strong.

Is There Hope for Better Coverage in the Future?

The landscape is evolving, though not always in patients’ favor.

Trends Working Against Coverage:

• Budget pressures: States like California and Pennsylvania are eliminating Medicaid coverage due to costs exceeding $100 million annually
• Employer concerns: Large employers are excluding or heavily restricting obesity medication coverage due to projected spending increases
• Medicare restrictions: Federal law still prohibits Part D coverage of weight-loss drugs (would require congressional action to change)

Trends Working For Coverage:

• Cardiovascular benefits: Wegovy’s approval for heart disease prevention opened a coverage pathway in Medicare—similar approvals for other conditions could expand access
• Long-term cost savings: Research showing GLP-1s reduce obesity-related healthcare costs may eventually persuade payers (though this is a multi-year timeline)
• Legislative efforts: Some states are considering mandates requiring coverage of FDA-approved obesity medications (though most have stalled due to cost concerns)
• Biosimilars on the horizon: Patents on these medications extend into the 2030s, but the eventual arrival of generic or biosimilar versions could dramatically reduce costs and expand coverage

The reality: For the next several years, accessing GLP-1 medications will likely require either strong insurance benefits (often through large employers), meeting strict PA criteria, or paying out-of-pocket with manufacturer assistance.

Making Your Insurance Work for You: Action Steps

Before Starting Treatment:

1. Call your insurance company and ask specifically:

• ‘Is Wegovy/Ozempic/Mounjaro covered on my formulary?’
• ‘What is the prior authorization criteria?’
• ‘What is my copay or coinsurance for this medication?’
• ‘Are there step therapy requirements?’

1. Request a formulary exceptions if the medication isn’t covered but you have a compelling medical need

2. Document everything related to your weight-loss journey from the start—this creates the paper trail insurers require

During Treatment:

4. Keep detailed records of all appointments, weight measurements, diet/exercise efforts, and side effects or benefits

5. Schedule regular follow-ups to document ongoing medical necessity for re-authorizations

6. Communicate with your provider about any insurance issues immediately—they can often intervene or adjust documentation

If Coverage Is Denied:

7. Appeal promptly with comprehensive documentation

8. Explore manufacturer programs while you appeal

9. Consider alternative coverage (spouse’s insurance, Marketplace plans during open enrollment, etc.)

10. Connect with patient advocacy organizations for assistance navigating complex insurance issues

Finding Affordable Access to GLP-1 Medications

Insurance coverage for GLP-1 medications in 2025 remains complex and often frustrating. While diabetes-indicated medications like Ozempic and Mounjaro are generally covered with prior authorization, weight-loss medications like Wegovy face significant barriers—from strict medical necessity criteria to outright plan exclusions.

The key takeaways:

• Commercial insurance varies widely; coverage depends on your employer’s plan design
• Medicare covers diabetes uses but excludes weight-loss-only indications
• Medicaid coverage is state-dependent and shrinking due to budget pressures
• Prior authorization is nearly universal and requires thorough documentation
• Self-pay options have improved significantly with manufacturer programs and GoodRx partnerships, bringing costs down to $199-$349 monthly from $1,000+

At Klarity Health, we believe cost should not be a barrier to effective weight management and diabetes care. Our telehealth platform provides transparent pricing for provider visits, accepts both insurance and cash pay, and our clinicians are available to prescribe GLP-1 medications when medically appropriate. We work with patients to navigate insurance coverage, explore manufacturer savings programs, and find the most affordable path to treatment.

Whether you’re dealing with type 2 diabetes, struggling with obesity-related health conditions, or simply trying to understand your insurance benefits, our providers are here to help. Schedule a consultation today to discuss your options and get the treatment you deserve.

Frequently Asked Questions

Does insurance cover Wegovy for weight loss?
Some commercial plans cover Wegovy with strict prior authorization requirements (BMI ≥30 or ≥27 with comorbidity, documented diet/exercise attempts). Medicare and many Medicaid programs do not cover it for weight loss. Check your specific plan’s formulary and PA criteria.

Will my insurance cover Ozempic if I don’t have diabetes?
No. Insurance will only cover Ozempic for FDA-approved uses, primarily type 2 diabetes. Using it solely for weight loss will result in claim denial. If you want GLP-1 coverage for weight loss, you’d need Wegovy (if your plan covers it).

What’s the cheapest way to get these medications without insurance?
GoodRx’s partnership program offers Wegovy/Ozempic at $199/month for the first two months, then $349/month. Manufacturer patient assistance programs provide free medication to eligible low-income patients. Novo Nordisk and Eli Lilly both offer savings cards that can reduce costs significantly.

How long does prior authorization take?
Typically 5-7 business days for standard requests, 24-72 hours for urgent/expedited requests. Some insurers respond faster (2-3 days), while others take the full timeframe. Your provider can check authorization status by calling the insurance company.

Can I appeal if my insurance denies coverage?
Yes. Most plans allow at least two levels of appeals. Gather comprehensive medical documentation, have your doctor write a letter of medical necessity, and submit a formal written appeal. Many denials are overturned when complete documentation is provided. External review through your state insurance department is available if internal appeals fail.

Does Medicare cover any GLP-1 medications?
Medicare Part D covers Ozempic and Mounjaro for type 2 diabetes. It covers Wegovy only for cardiovascular risk reduction in obese patients with heart disease, not for general weight loss (federal law excludes weight-loss drugs from Part D). Medicare Advantage plans may offer limited coverage in some cases.

📅 Research Currency Statement (Verified as of December 17, 2025)

This article reflects insurance coverage policies, formulary information, and pricing as of December 2025. Insurance coverage for GLP-1 medications is rapidly changing—several states eliminated Medicaid coverage on January 1, 2026, and manufacturer pricing programs launched in late 2025. Always verify current coverage with your insurance provider and check for the latest manufacturer savings programs before starting treatment.

References

1. Aetna Clinical Policy Bulletin – Weight Loss GLP-1 Agonists, May 2024. www.aetna.com

2. California Department of Health Care Services. ‘GLP-1 medications for weight loss will no longer be covered by Medi-Cal,’ December 2025. www.cmadocs.org

3. Cohen, J. ‘Coverage of Weight Loss Drugs by Medicaid Plans Continues to Lag,’ Forbes, August 7, 2025. www.forbes.com

4. Kaiser Family Foundation. ‘Medicaid Coverage of and Spending on GLP-1s,’ November 4, 2024. www.kff.org

5. GoodRx. ‘GoodRx Launches New $39-Per-Month Weight Loss Telemedicine Subscription,’ BusinessWire, November 17, 2025. www.businesswire.com

Source:

• https://www.aetna.com/products/rxnonmedicare/data/2024/WeightLoss%28BMI%2035%29GIP-GLP-1GLP-1AgonistsPAwithLimit6450-CUDR_05-2024.html#:~:text=%C2%B0Wegovy%3A%20Initial%20therapy%20DOA%3A%207,based%20on%20the%20following%20references
• https://www.singlecare.com/blog/cigna-prior-authorization-weight-loss/#:~:text=Cigna%20coverage%20criteria%20for%20GLP,drugs
• https://www.amwinsconnect.com/news/kaiser-permanenter-coverage-changes-glp-1-drugs-and-anti-obesity-medications-2025#:~:text=drugs%20and%20other%20AOMs%20will,with%20BMI%20less%20than%2040
• https://www.texaschildrenshealthplan.org/2023/04/28/provider-alert-non-formulary-requests-for-obesity-control-drugs#:~:text=for%20obesity%20control%20drugs%20for,Imcivree%2C%20Qysmia%2C%20Saxenda%20and%20Wegovy
• https://www.phlp.org/en/news/pennsylvania-medicaid-covers-newer-weight-loss-drugs#:~:text=Generally%2C%20to%20get%20these%20drugs,CDC%29%20charts
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=What%20You%20Need%20to%20Know%3A,Cal%20managed%20care
• https://solutionshortcut.com/medicaid-drug-coverage-by-state-2025-2026-updates/#:~:text=VDP%20PDL%20%26%20criteria%3B%20last,com
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=%2A%20Three%20GLP,covered%20after%20January%201%2C%202026
• https://www.forbes.com/sites/joshuacohen/2025/08/07/coverage-of-weight-loss-drugs-by-medicaid-plans-continues-to-lag/#:~:text=Medicaid%2C%20a%20federal,employees%20due%20to%20cost%20concerns
• https://www.fiercepharma.com/marketing/novo-unveils-newly-reduced-self-pay-prices-wegovy-ozempic-after-white-house-deal#:~:text=Novo%20revealed%20Monday%20that%20the,will%20still%20run%20for%20%24499